Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
78.56
+0.96 (1.24%)
At close: Sep 26, 2025, 4:00 PM EDT
78.66
+0.10 (0.13%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.12
Revenue / Employee
$848,213
Employees
75,000
Market Cap
196.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
MRK News
- 2 days ago - Merck: Game-Changing Oncology Drugs Power Stock Surge - Seeking Alpha
- 3 days ago - Merck: 25% Total Return CAGR Potential - Seeking Alpha
- 5 days ago - Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery - Business Wire
- 6 days ago - Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield - Seeking Alpha
- 8 days ago - Undercovered Dozen: Applied Digital, Merck, B2Gold And More - Seeking Alpha
- 9 days ago - FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) - Business Wire
- 9 days ago - US FDA approves Merck's new injectable version of Keytruda - Reuters
- 9 days ago - EMA committee recommends approval for injectable version of Merck's Keytruda - Reuters